SGLT2 Inhibitors and Kidney and Cardiac Outcomes According to Estimated GFR and Albuminuria Levels: A Meta-analysis of Randomized Controlled Trials.

ABSTRACT:

Rationale & objective

There are few data on the absolute effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors, despite their importance in treatment decision making. We investigated absolute treatment effects according to baseline kidney disease status.

Study design

Meta-analysis.

Study populations

Adults with type 2 diabetes, chronic kidney disease, or heart failure.

Selection criteria for studies

Randomized controlled trials of SGLT2 inhibitors (10 trials to November 20, 2020) for clinical outcomes of kidney disease progression, heart failure events, and major cardiovascular events.

Data extraction

Publications of 10 trials to November 20, 2020.

Analytical approach

The incidence rate difference (IRD) between SGLT2 inhibitor and placebo w

SUBMITTER: Chun KJ 

PROVIDER: S-EPMC8551546 | biostudies-literature | 2021 Sep-Oct

REPOSITORIES: biostudies-literature